PROTAGONIST THERAPEUTICS INC(NASDAQ:PTGX) stock Fundamental Analysis

Fundamental Rating

PTGX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. While PTGX has a great health rating, its profitability is only average at the moment. PTGX has a decent growth rate and is not valued too expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

PTGX had positive earnings in the past year.

PTGX had a positive operating cash flow in the past year.

In the past 5 years PTGX reported 4 times negative net income.

In the past 5 years PTGX reported 4 times negative operating cash flow.

1.2 Ratios

With an excellent Return On Assets value of 36.95%, PTGX belongs to the best of the industry, outperforming 99.30% of the companies in the same industry.

PTGX has a Return On Equity of 40.75%. This is amongst the best in the industry. PTGX outperforms 98.77% of its industry peers.

PTGX's Return On Invested Capital of 28.64% is amongst the best of the industry. PTGX outperforms 99.65% of its industry peers.

		Industry Rank	Sector Rank
ROA	36.95%
ROE	40.75%
ROIC	28.64%

ROA(3y)-12.16%

ROA(5y)-18.6%

ROE(3y)-13.93%

ROE(5y)-21.46%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PTGX has a better Profit Margin (63.34%) than 99.47% of its industry peers.

The Operating Margin of PTGX (58.20%) is better than 100.00% of its industry peers.

		Industry Rank	Sector Rank
OM	58.2%
PM (TTM)	63.34%
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PTGX is creating value.

PTGX has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, PTGX has more shares outstanding

There is no outstanding debt for PTGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

PTGX has an Altman-Z score of 26.43. This indicates that PTGX is financially healthy and has little risk of bankruptcy at the moment.

PTGX has a better Altman-Z score (26.43) than 95.95% of its industry peers.

PTGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	26.43

ROIC/WACC2.78

WACC10.3%

2.3 Liquidity

PTGX has a Current Ratio of 12.48. This indicates that PTGX is financially healthy and has no problem in meeting its short term obligations.

PTGX's Current ratio of 12.48 is amongst the best of the industry. PTGX outperforms 85.21% of its industry peers.

A Quick Ratio of 12.48 indicates that PTGX has no problem at all paying its short term obligations.

The Quick ratio of PTGX (12.48) is better than 85.21% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	12.48
Quick Ratio	12.48

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

PTGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 381.88%, which is quite impressive.

Looking at the last year, PTGX shows a very strong growth in Revenue. The Revenue has grown by 624.05%.

PTGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 352.10% yearly.

EPS 1Y (TTM)381.88%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%350%

Revenue 1Y (TTM)624.05%

Revenue growth 3Y151.34%

Revenue growth 5Y352.1%

Sales Q2Q%184.4%

3.2 Future

The Earnings Per Share is expected to decrease by -1.91% on average over the next years.

PTGX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.46% yearly.

EPS Next Y-142.81%

EPS Next 2Y-53.45%

EPS Next 3Y-32.64%

EPS Next 5Y-1.91%

Revenue Next Year-69.2%

Revenue Next 2Y-42.56%

Revenue Next 3Y-25.04%

Revenue Next 5Y7.46%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 10.68 indicates a reasonable valuation of PTGX.

Compared to the rest of the industry, the Price/Earnings ratio of PTGX indicates a rather cheap valuation: PTGX is cheaper than 97.54% of the companies listed in the same industry.

When comparing the Price/Earnings ratio of PTGX to the average of the S&P500 Index (28.92), we can say PTGX is valued rather cheaply.

The Forward Price/Earnings Ratio is negative for PTGX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	10.68
Fwd PE	N/A

4.2 Price Multiples

PTGX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PTGX is cheaper than 97.89% of the companies in the same industry.

PTGX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PTGX is cheaper than 96.13% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	15.06
EV/EBITDA	8.18

4.3 Compensation for Growth

A cheap valuation may be justified as PTGX's earnings are expected to decrease with -32.64% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-53.45%

EPS Next 3Y-32.64%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

PTGX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PROTAGONIST THERAPEUTICS INC

NASDAQ:PTGX (4/24/2025, 8:00:00 PM)

After market: 44.8 -0.05 (-0.11%)

44.85

-1.31 (-2.84%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)02-21 2025-02-21/bmo

Earnings (Next)04-30 2025-04-30/amc

Inst Owners106.3%

Inst Owner Change0.06%

Ins Owners1.46%

Ins Owner Change-0.9%

Market Cap2.75B

Analysts83.75

Price Target70.83 (57.93%)

Short Float %8.27%

Short Ratio5.32

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)258.69%

Min EPS beat(2)12.85%

Max EPS beat(2)504.52%

EPS beat(4)4

Avg EPS beat(4)175.91%

Min EPS beat(4)12.85%

Max EPS beat(4)504.52%

EPS beat(8)7

Avg EPS beat(8)265.95%

EPS beat(12)10

Avg EPS beat(12)182.78%

EPS beat(16)12

Avg EPS beat(16)136.1%

Revenue beat(2)2

Avg Revenue beat(2)176.74%

Min Revenue beat(2)121.25%

Max Revenue beat(2)232.24%

Revenue beat(4)3

Avg Revenue beat(4)103.21%

Min Revenue beat(4)-48.93%

Max Revenue beat(4)232.24%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)17.92%

PT rev (3m)20.77%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-125.33%

EPS NY rev (1m)-21.85%

EPS NY rev (3m)-16.28%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-29.65%

Revenue NY rev (1m)-9.15%

Revenue NY rev (3m)22.57%

Valuation

		Industry Rank	Sector Rank
PE	10.68
Fwd PE	N/A
P/S	6.34
P/FCF	15.06
P/OCF	14.95
P/B	4.08
P/tB	4.08
EV/EBITDA	8.18

EPS(TTM)4.2

EY9.36%

EPS(NY)-1.8

Fwd EYN/A

FCF(TTM)2.98

FCFY6.64%

OCF(TTM)3

OCFY6.69%

SpS7.08

BVpS11

TBVpS11

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	36.95%
ROE	40.75%
ROCE	36.26%
ROIC	28.64%
ROICexc	71.74%
ROICexgc	71.74%
OM	58.2%
PM (TTM)	63.34%
GM	N/A
FCFM	42.08%

ROA(3y)-12.16%

ROA(5y)-18.6%

ROE(3y)-13.93%

ROE(5y)-21.46%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.58

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	0
Cap/Depr	46.8%
Cap/Sales	0.31%
Interest Coverage	250
Cash Conversion	72.01%
Profit Quality	66.43%
Current Ratio	12.48
Quick Ratio	12.48
Altman-Z	26.43

F-Score6

WACC10.3%

ROIC/WACC2.78

Cap/Depr(3y)47.62%

Cap/Depr(5y)67.63%

Cap/Sales(3y)1.45%

Cap/Sales(5y)2%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)381.88%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%350%

EPS Next Y-142.81%

EPS Next 2Y-53.45%

EPS Next 3Y-32.64%

EPS Next 5Y-1.91%

Revenue 1Y (TTM)624.05%

Revenue growth 3Y151.34%

Revenue growth 5Y352.1%

Sales Q2Q%184.4%

Revenue Next Year-69.2%

Revenue Next 2Y-42.56%

Revenue Next 3Y-25.04%

Revenue Next 5Y7.46%

EBIT growth 1Y369.98%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-195.16%

EBIT Next 3Y-21.56%

EBIT Next 5YN/A

FCF growth 1Y358.02%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y362.19%

OCF growth 3YN/A

OCF growth 5YN/A

PROTAGONIST THERAPEUTICS INC (PTGX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens